These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27864124)

  • 1. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
    Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
    Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
    Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD47 expression and CD163
    Imam R; Chang Q; Black M; Yu C; Cao W
    BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.
    Schmitt AM; Anlauf M; Rousson V; Schmid S; Kofler A; Riniker F; Bauersfeld J; Barghorn A; Probst-Hensch NM; Moch H; Heitz PU; Kloeppel G; Komminoth P; Perren A
    Am J Surg Pathol; 2007 Nov; 31(11):1677-82. PubMed ID: 18059224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
    Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.
    Zhang L; Smyrk TC; Oliveira AM; Lohse CM; Zhang S; Johnson MR; Lloyd RV
    Am J Surg Pathol; 2009 Oct; 33(10):1562-9. PubMed ID: 19574886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations and expression of PTEN and its relationship with cancer stem cell markers to investigate pathogenesis and to evaluate prognosis in hepatocellular carcinoma.
    Chen D; Li Z; Cheng Q; Wang Y; Qian L; Gao J; Zhu JY
    J Clin Pathol; 2019 Sep; 72(9):588-596. PubMed ID: 31126975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
    Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
    Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).
    Cai L; Michelakos T; Deshpande V; Arora KS; Yamada T; Ting DT; Taylor MS; Castillo CF; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    Clin Cancer Res; 2019 Apr; 25(8):2644-2655. PubMed ID: 30670493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
    Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
    J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
    Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
    Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of WHO Classifications (2004, 2010), the Hochwald grading system, and AJCC and ENETS staging systems in predicting prognosis in locoregional well-differentiated pancreatic neuroendocrine tumors.
    Liu TC; Hamilton N; Hawkins W; Gao F; Cao D
    Am J Surg Pathol; 2013 Jun; 37(6):853-9. PubMed ID: 23598967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
    Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
    J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms.
    Simtniece Z; Vanags A; Strumfa I; Sperga M; Vasko E; Prieditis P; Trapencieris P; Gardovskis J
    Pol J Pathol; 2015 Jun; 66(2):176-94. PubMed ID: 26247532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.